MetabolicPreliminary grade

Survodutide

Boehringer Ingelheim's dual GLP-1/glucagon agonist in phase-3 for obesity and MASH — strong phase-2 signal.

Verdict — C · Emerging / Mixed

A differentiated mechanism with strong phase-2 data in obesity and MASH, but no approval and no verified source. A C pending SYNCHRONIZE readout.

PepScore / 100

CEmerging / Mixed

How we compute this →

Overview

Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist in phase-3 SYNCHRONIZE trials for obesity and metabolic-associated steatohepatitis (MASH). Phase-2 data showed approximately 19% weight loss. MASH is an area of significant unmet need and the glucagon axis adds hepatic benefit beyond GLP-1 alone. No approval exists; no verified gray-market supply.

PepScore Breakdown — the four axes

Evidence

35% weight

73/100

How strong is the published human science?

Human data depth28/40

Regulatory & registry status24/30

Reproducibility & consistency13/20

Mechanism characterized in humans8/10

Sourcing & COA

30% weightOur moat

39/100

Can a buyer obtain an independently-verified, high-purity version? — our proprietary layer.

Independent 3rd-party testing14/35

Verified purity %12/30

COA transparency & batch traceability8/20

Multi-vendor verified availability5/15

Safety & Risk

25% weight

48/100

What is the real-world harm potential?

Documented AEs / toxicity18/40

Contraindication breadth11/25

Regulatory warnings10/20

Therapeutic index / margin9/15

Practicality

10% weight

51/100

How easy is it to actually run a verified version?

Verified-source availability14/35

Cost / value per cycle12/25

Reconstitution & administration16/25

Storage & stability9/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.

Want a clinical path?

Talk to a licensed provider about Survodutide and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice — for educational purposes.

PepScore54/100 · C

Last gradedJune 28, 2026

Next re-grade triggerFDA approval for MASH or obesity would lift all axes materially.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.

Free. Unsubscribe anytime. Research/educational content only.

Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.